Cardiac Congenital and Valvular Disorders with MCC DRG Reimbursement

DRG 306 addresses complex cardiac congenital and valvular disorders with a Major Complication or Comorbidity, including cases that require major surgical procedures or intensive medical care. This Diagnosis-Related Group is important for inpatient reimbursement because the presence of a Major Complication or Comorbidity raises the payment weight to account for higher resource use and longer expected lengths of stay.

DRG 306 Overview

DRG 306 covers inpatient hospitalizations for complex cardiac congenital and valvular disorders when a Major Complication or Comorbidity is present, typically involving significant surgical intervention or advanced medical management. This Diagnosis-Related Group captures cases with higher resource intensity due to severe cardiac pathology, complications, or need for intensive postoperative care. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative weight and prospective reimbursement to reflect greater expected costs. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and therefore influence inpatient reimbursement.

Trials of perioperative strategies to reduce morbidity and mortality in high-risk congenital and valvular cardiac surgery patients: randomized or pragmatic studies testing timing of surgery, blood conservation protocols, and optimized perioperative monitoring in neonates, infants, or adults with complex congenital lesions or severe valvular disease complicated by major comorbidities. These studies enroll patients admitted for corrective or reparative cardiac procedures with major complications or secondary organ dysfunction (the MCC population) to evaluate short-term endpoints such as ICU length of stay, rates of postoperative organ failure, and in-hospital mortality. Results are highly relevant to providers and payers because improved perioperative protocols can decrease intensive resource use and costly complications that drive DRG payments for this group.
Comparative effectiveness and device/intervention trials for valve repair versus replacement and minimally invasive approaches in patients with complex valvular disease and congenital heart defects: cohort or randomized studies comparing outcomes of transcatheter, minimally invasive surgical, and open surgical techniques in heterogeneous patients including those with prior surgeries or multiple comorbidities. These studies focus on procedural success, need for reintervention, periprocedural complications, and mid-term functional status in the high-acuity MCC cohort to define which approaches yield better safety and durability for sicker patients. Findings inform clinical decision-making and utilization patterns that impact hospital resource allocation and reimbursement, helping payers evaluate value of newer, often more costly technologies for this DRG.
Post-discharge longitudinal outcome and care-coordination studies assessing readmissions, functional recovery, and cost trajectories among survivors of complex congenital or valvular cardiac admissions with major complications: observational and intervention studies testing enhanced discharge planning, remote monitoring, or structured multidisciplinary follow-up versus usual care. These trials enroll patients discharged after hospitalization with significant postoperative complications or organ dysfunction to measure 30- and 90-day readmission rates, outpatient resource use, patient-reported outcomes, and total episode-of-care costs. This research matters to providers and payers by identifying strategies to reduce preventable readmissions and downstream expenditures, optimize care transitions, and improve patient outcomes within the reimbursement framework for DRG 306.

Trials of perioperative strategies to reduce morbidity and mortality in high-risk congenital and valvular cardiac surgery patients: randomized or pragmatic studies testing timing of surgery, blood conservation protocols, and optimized perioperative monitoring in neonates, infants, or adults with complex congenital lesions or severe valvular disease complicated by major comorbidities. These studies enroll patients admitted for corrective or reparative cardiac procedures with major complications or secondary organ dysfunction (the MCC population) to evaluate short-term endpoints such as ICU length of stay, rates of postoperative organ failure, and in-hospital mortality. Results are highly relevant to providers and payers because improved perioperative protocols can decrease intensive resource use and costly complications that drive DRG payments for this group.
Comparative effectiveness and device/intervention trials for valve repair versus replacement and minimally invasive approaches in patients with complex valvular disease and congenital heart defects: cohort or randomized studies comparing outcomes of transcatheter, minimally invasive surgical, and open surgical techniques in heterogeneous patients including those with prior surgeries or multiple comorbidities. These studies focus on procedural success, need for reintervention, periprocedural complications, and mid-term functional status in the high-acuity MCC cohort to define which approaches yield better safety and durability for sicker patients. Findings inform clinical decision-making and utilization patterns that impact hospital resource allocation and reimbursement, helping payers evaluate value of newer, often more costly technologies for this DRG.
Post-discharge longitudinal outcome and care-coordination studies assessing readmissions, functional recovery, and cost trajectories among survivors of complex congenital or valvular cardiac admissions with major complications: observational and intervention studies testing enhanced discharge planning, remote monitoring, or structured multidisciplinary follow-up versus usual care. These trials enroll patients discharged after hospitalization with significant postoperative complications or organ dysfunction to measure 30- and 90-day readmission rates, outpatient resource use, patient-reported outcomes, and total episode-of-care costs. This research matters to providers and payers by identifying strategies to reduce preventable readmissions and downstream expenditures, optimize care transitions, and improve patient outcomes within the reimbursement framework for DRG 306.

OpenPayer

Summary & Overview

Cardiac Congenital and Valvular Disorders with MCC: Inpatient Reimbursement Overview

DRG 306 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes